Anixa Biosciences is trading 6.2% up at $3.78 in pre-market, appearing to track a broader risk-on sentiment across U.S. equities.
- The move extends a modest gain from July 30 as the stock rebounds from recent volatility.
- There are no fresh company-specific catalysts, earnings reports, or FDA updates to account for the price action.
- Major indices and tech futures are trading higher ahead of the open, providing a supportive backdrop for the stock.